ClinicalTrials.gg
RecruitingNCT05058651Updated Nov 20, 2026

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

A Phase 2/3 interventional study of Atezolizumab and Biospecimen Collection in Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma and Recurrent Extrapulmonary Neuroendocrine Carcinoma, sponsored by National Cancer Institute (NCI). Recruiting at 267 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by National Cancer Institute (NCI) · Phase 2/3, Interventional, and Treatment

How we know · 9 judgments

From the registry’s dates

  • Started Jun 2022; still recruiting 4 years 4 months later.
Updated Nov 20, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
189
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Carcinoma, Neuroendocrine by National Cancer Institute (NCI) — 5 open to participants now, 7 under way, 1 of them phase 3. Carcinoma, Neuroendocrine · National Cancer Institute (NCI).

Planned enrollment
Largest of 10
189 · median 50
Started
2022
with 1 other
Phase 2/3
Only one
of the 12
Registered
8th of 12
by date

Among the 12 studies in Carcinoma, Neuroendocrine by National Cancer Institute (NCI), this one has the largest planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2022, is the only one in phase 2/3, and was the 8th registered.

Carcinoma, Neuroendocrine

172 studies on the registry are indexed under Carcinoma, Neuroendocrine; 65 are open to participants now.

Browse Carcinoma, Neuroendocrine studies →

Open to participants now

5 of the 12 studies in Carcinoma, Neuroendocrine by National Cancer Institute (NCI) are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 46 Carcinoma, Neuroendocrine studies recruiting now, 29 (63%) set no upper age limit and 10 (22%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Carcinoma, Neuroendocrine by National Cancer Institute (NCI), or all of them as a file.
02

Study summary

This phase II/III trial compares the effect of immunotherapy with atezolizumab in combination with standard chemotherapy with a platinum drug (cisplatin or carboplatin) and etoposide versus standard therapy alone for the treatment of poorly differentiated extrapulmonary (originated outside the lung) neuroendocrine cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). The other aim of this trial is to compare using atezolizumab just at the beginning of treatment versus continuing it beyond the initial treatment. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cisplatin and carboplatin are in a class of medications known as platinum-containing compounds that work by killing, stopping or slowing the growth of cancer cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. Giving atezolizumab in combination with a platinum drug (cisplatin or carboplatin) and etoposide may work better in treating patients with poorly differentiated extrapulmonary neuroendocrine cancer compared to standard therapy with a platinum drug (cisplatin or carboplatin) and etoposide alone.

Read the detailed description

PRIMARY OBJECTIVES:

I. Compare the combination of induction platinum/etoposide and atezolizumab followed by maintenance atezolizumab (Arm 1) versus induction platinum/etoposide alone (Arm 3).

II. Compare the combination of induction platinum/etoposide and atezolizumab followed by observation (Arm 2) versus induction platinum/etoposide alone (Arm 3).

III. Compare the combination of induction platinum/etoposide and atezolizumab followed by maintenance atezolizumab (Arm 1) versus the combination of induction platinum/etoposide and atezolizumab followed by observation (Arm 2).

SECONDARY OBJECTIVES:

I. To compare overall survival (OS), measured from start of observation/maintenance, across arms.

II. To compare progression free survival (PFS) (measured from randomization and measured from start of observation/maintenance) across arms.

III. To compare objective response rate (ORR = confirmed and unconfirmed partial response [PR] + confirmed and unconfirmed complete response [CR]) across arms among patients with measurable disease at randomization.

IV. To compare clinical benefit rate (CBR = confirmed and unconfirmed PR + confirmed and unconfirmed CR + stable disease [SD]) across arms among patients with measurable disease at randomization.

V. To compare duration of response (DOR) across arms. VI. To evaluate the safety and tolerability of each arm.

ADDITIONAL OBJECTIVE:

I. To bank tumor and blood samples for future biomarker correlative studies.

OUTLINE: Patients are randomized to 1 of 3 arms.

ARM I: During induction phase, patients receive atezolizumab intravenously (IV) over 30-60 minutes on day 1 of each cycle, carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle, and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. During maintenance phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity.

ARM II (CLOSED TO ACCRUAL 7/9/26): During induction phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle, carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle, and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo observation for 1 year.

ARM III: During induction phase, patients receive carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo observation for 1 year.

Patients in all arms also undergo computed tomography (CT) scan and/or magnetic resonance imaging (MRI) throughout the trial and blood sample collection on study.

After completion of study treatment, patients are followed up for 5 years.

03

Conditions studied

  • Advanced Extrapulmonary Neuroendocrine Carcinoma
  • Metastatic Extrapulmonary Neuroendocrine Carcinoma
  • Recurrent Extrapulmonary Neuroendocrine Carcinoma
  • Unresectable Extrapulmonary Neuroendocrine Carcinoma
04

Who can participate

The criteria were revised on the registry on Sep 30, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Participants must have -confirmed (local site pathological confirmation sufficient) extrapulmonary poorly differentiated, neuroendocrine carcinoma (NEC)
  • Participants must have disease that is unresectable or and not eligible for definitive therapy as deemed per the treating investigator
  • Participants must have radiologically evaluable disease, measurable or non-measurable, per (RECIST) 1.1 criteria. All measurable and nonmeasurable lesions must be assessed by CT scan with IV contrast of the chest/abdomen/and pelvis (or CT chest without contrast and MRI abdomen/pelvis with gadolinium contrast, if to CT iodinated contrast) within 28 days prior to registration. While may be used for routine clinical evaluation, PET scans and bone scans alone are not acceptable for disease assessment while participating in this study. All known sites of disease must be assessed and documented on the Baseline Tumor Assessment Form
  • Participants must have brain MRI (or CT head with contrast if there is contraindication to MRI brain) if clinically indicated within 28 days prior to registration. Note: Brain imaging is not required in participants without known and/or clinical concern for . Participants with asymptomatic central nervous system (CNS) metastases are eligible if one or more of the following apply:

    • Participants who have received treatment for brain metastases must have:

      • No evidence of radiological progression (by MRI brain or CT head with contrast if there is contraindication to MRI brain) within 28 days prior to registration
      • Discontinued all at least 14 days prior to registration
    • Participants with treatment-naive brain lesions must have:

      • No lesion measuring > 2.0 cm in size in any axis
      • MRI brain or CT head with contrast (if there is contraindication to MRI brain) demonstrating no evidence for mass effect, edema, or other impending neurological compromise within 28 days prior to registration
      • No evidence of radiological progression (by MRI brain or CT head with contrast if there is contraindication to MRI brain) within 28 days prior to registration
      • No need for > 2 mg of dexamethasone (or equivalent of > 10 mg prednisone) per day at time of registration
  • Participants must not have symptomatic central nervous system (CNS) metastases
  • Participants must not have known or suspected
  • Participants with prior history of non-metastatic (localized/locally advanced disease) extrapulmonary poorly differentiated NEC may have had prior platinum-based therapy +/- radiation +/- surgery provided that all therapy was completed >= 6 months prior to registration
  • Participants must discontinue denosumab prior to study registration and plan to replace with a bisphosphonate while on the study
  • Participants must not have had prior treatment for advanced or metastatic NEC EXCEPT one cycle of platinum (carboplatin/cisplatin) + etoposide is allowed prior to registration. Other chemotherapy regimens are not allowed. For participants with prostate or urothelial NEC, prior chemotherapy for the non-NEC component (e.g. adenocarcinoma or urothelial) is allowed as long as such therapy was completed >= 24 weeks prior to registration and participants have recovered from all prior toxicities to =\< grade 1.
  • Participants must not have had prior treatment with an , anti-PD-L1, antiPD-L2, CD137 agonists, anti-CTLA-4 agent, or any other immune checkpoint inhibitors for any neuroendocrine neoplasm. Immune checkpoint inhibitors given for other cancer indications are allowed provided last therapy was given at least 12 months prior to study registration
  • Participants must not have received treatment with systemic immunostimulatory agents including, but not limited to, interferon and interleukin2 [IL-2] within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to registration
  • Participants must not have had history of known severe allergy, anaphylactic, or other reactions to chimeric or humanized antibodies, including to Chinese hamster ovary cell products or to any component of the atezolizumab formulation, cisplatin, carboplatin, or etoposide
  • Participants must not be on active systemic therapy for another cancer with the exception of hormonal therapy including androgen deprivation therapy (e.g., gonadotropin-releasing hormone [GnRH] agonists or antagonists), which can be continued while participants are receiving protocol therapy. Use of enzalutamide or apalutamide is permitted after completion of chemotherapy and must be held during chemotherapy for participants receiving prior to enrollment. Use of darolutamide is permitted during chemotherapy. Glucocorticoid-containing regimens, including abiraterone, are not permitted.
  • Participants must be >= 18 years of age
  • Participants must have a Zubrod performance status of =\< 2 within 28 days prior to registration
  • Participants must have a complete medical history and physical exam within 28 days prior to registration
  • (ANC) >= 1.5 x 10\^9 /L (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)
  • >= 9.0 g/dl (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)
  • count >= 100 x 10\^9/L (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)
  • Serum (ALT) and aspartate aminotransferase (AST) =\< 2.5 x institutional (ULN) (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)
  • Serum total =\< 1.5 x ULN (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)
  • Adequate renal function as defined by any 1 of the following: 1) Measured (CL) > 50 mL/min OR 2) Calculated creatinine CL > 50 mL/min by the Cockcroft-Gault formula OR by 24-hour urine collection for determination of creatinine clearance (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)
  • Participants must not have uncontrolled or symptomatic hypercalcemia (> 1.5 mmol/L ionized calcium or calcium > 12 mg/dL or corrected serum calcium > ULN) within 14 days prior to registration. Participants who have asymptomatic hypercalcemia are eligible provided that medical therapy to treat the hypercalcemia is planned
  • Participants must not have a diagnosis of immunodeficiency nor be receiving systemic steroid therapy (equivalent of > 20 mg of hydrocortisone per day) or any other form of therapy within 14 days prior to registration
  • Participants must not have active or history of disease or immune deficiency, including, but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjogren syndrome, Guillain-Barre syndrome, or multiple sclerosis with the following exceptions:

    • Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study
    • Patients with controlled type 1 diabetes mellitus who are on an insulin regimen are eligible for the study
    • Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:

      • Rash must cover \< 10% of body surface area
      • Disease is well controlled at baseline and requires only low-potency topical corticosteroids
      • No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months
  • Participants must not have history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan. NOTE: History of radiation pneumonitis in the radiation field (fibrosis) is permitted
  • Participants must not have significant cardiovascular disease, such as class II or greater cardiac disease, myocardial infarction within 3 months prior to registration, unstable arrythmias, or unstable angina
  • Participants must not have had a major surgical procedure other than for diagnosis within 28 days prior to registration. Participant must not plan to receive a major surgical procedure during the course of protocol treatment. NOTE: Patient port placement is not considered a major surgery
  • Participants must not have severe infections (i.e., [CTCAE] grade >= 2) at time of registration, including but not limited to hospitalization for complications for infection, bacteremia, or severe pneumonia
  • Participants must not have known active tuberculosis
  • Participants with evidence of chronic virus (HBV) infection must have undetectable HBV viral load, with testing performed as clinically indicated
  • Participants with a history of virus (HCV) infection must have been treated and cured. Participants with active HCV infection who are currently on treatment must have an undetectable HCV viral load, with testing performed as clinically indicated
  • Participants with known (HIV)-infection must be on effective anti-retroviral therapy at time of registration and have undetectable HIV viral load within 6 months of registration
  • Participants must not have prior bone marrow transplantation or solid organ transplant
  • Participants must not have received administration of a live, attenuated vaccine (e.g., FluMist [registered trademark]) within 28 days prior to initiation of study treatment, during treatment with atezolizumab, and not plan to receive for 5 months after the last dose of atezolizumab
  • Participants must not be pregnant due to the possibility of harm to the fetus. Individuals who are of must have agreed to use an effective method (with details provided as a part of the consent process) during the treatment period and for 5 months after the final dose of atezolizumab. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen
  • Participants must be offered the opportunity to participate in specimen banking. With participant consent, specimens must be collected and submitted via the Southwest Oncology Group (SWOG) Specimen Tracking System
  • Participants must be informed of the nature of this study and must sign and give in accordance with institutional and federal guidelines
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
189 participants (estimated)

Study arms

  • Experimental
    Arm I (atezolizumab, platinum drug, etoposide)

    During induction phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle, carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle, and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. During maintenance phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan and/or MRI throughout the trial and blood sample collection on study.

    Biological: Atezolizumab · Procedure: Biospecimen Collection · Drug: Carboplatin · Drug: Cisplatin · Procedure: Computed Tomography · Drug: Etoposide · Procedure: Magnetic Resonance Imaging

  • Experimental
    Arm II (atezolizumab, platinum drug, etoposide, observation)

    During induction phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle, carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle, and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo observation for 1 year. Patients also undergo CT scan and/or MRI throughout the trial and blood sample collection on study. (CLOSED TO ACCRUAL 7/9/26)

    Biological: Atezolizumab · Procedure: Biospecimen Collection · Drug: Carboplatin · Drug: Cisplatin · Procedure: Computed Tomography · Drug: Etoposide · Procedure: Magnetic Resonance Imaging · Other: Patient Observation

  • Active comparator
    Arm III (platinum drug, etoposide, observation)

    During induction phase, patients receive carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo observation for 1 year. Patients also undergo CT scan and/or MRI throughout the trial and blood sample collection on study.

    Procedure: Biospecimen Collection · Drug: Carboplatin · Drug: Cisplatin · Procedure: Computed Tomography · Drug: Etoposide · Procedure: Magnetic Resonance Imaging · Other: Patient Observation

Interventions

  • BiologicalAtezolizumab

    Given IV

    Also known as: MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • Given IV

    Also known as: Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo

  • Given IV

    Also known as: Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin

  • ProcedureComputed Tomography

    Undergo CT scan

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • Given IV

    Also known as: Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP-16213, VP16, VP16213

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • OtherPatient Observation

    Undergo observation

    Also known as: Active Surveillance, deferred therapy, expectant management, Observation, Watchful Waiting

06

What researchers measure

Primary outcomes

  1. Overall survival

    Log-rank tests stratified by the randomization stratification factors will be used for null hypothesis (efficacy) tests. Cox regression models stratified by the randomization stratification factors will be used for alternative hypothesis (futility) tests.

    Time frame: From date of registration or from date of start of observation/maintenance therapy to date of death due to any cause, assessed up to 5 years

Secondary outcomes

  1. Progression-free survival

    Will be estimated using the Kaplan-Meier method and compared using log-rank tests.

    Time frame: From date of registration or start of observation/maintenance therapy to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 5 years

  2. Duration of response

    Will be estimated non-parametrically using cumulative incidence curves.

    Time frame: Time from date of initial response to date of progression or death, assessed up to 5 years

  3. Objective response rate (confirmed complete response [CR] or partial response [PR])

    Will be tabulated and compared between arms using Fisher's exact test.

    Time frame: Up to 5 years from study enrollment

  4. Clinical benefit rate (confirmed CR or PR of any amount of time or stable disease for 6 months or longer)

    Will be tabulated and compared between arms using Fisher's exact test.

    Time frame: Up to 5 years from study enrollment

07

Study locations

244 of 267 sites recruiting

Showing the first 100 of 267 sites. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Moss D, O'Connor CA, Hilmi M, Tezcan N, Thummalapalli R, Chou JF, Perry M, Muldoon D, Bandlamudi C, Kim TH, Khalil DN, Ku G, Harding J, Goldberg Z, Etay Z, Iacobuzio C, Basturk O, Capanu M, Raj N, O'Reilly EM, Park W. Outcomes of Chemoimmunotherapy in Metastatic Pancreatic Neuroendocrine Carcinoma: A Single-Center Clinicopathologic Study. Oncologist. 2026 Oct 28:oyag429. doi: 10.1093/oncolo/oyag429. Online ahead of print. PubMed 42949119 ↗

Individual participant data

Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Data sharing details ↗ · grants.nih.gov

09

Timeline

17 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2022 (actual). Primary completion is estimated for Oct 2028, 75 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2021
First posted
Sep 28, 2021
StartActual
Jun 28, 2022
Primary completionEst.
Oct 1, 2028
CompletionEst.
Oct 1, 2028
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Suspended→Recruiting Reason for stopping removed
changed Sep 30, 2026
Sites
12 sites added. 255 sites changed recruiting status (232 now recruiting, 15 now suspended, …)
Show 255 sites
  • Alaska Women's Cancer Care · Anchorage, United Statesno status→Suspended
  • Cancer Center at Saint Joseph's · Phoenix, United Statesno status→Recruiting
  • Mayo Clinic Hospital in Arizona · Phoenix, United Statesno status→Recruiting
  • Kaiser Permanente-Anaheim · Anaheim, United Statesno status→Recruiting
  • Sutter Auburn Faith Hospital · Auburn, United Statesno status→Recruiting
  • Sutter Cancer Centers Radiation Oncology Services-Auburn · Auburn, United Statesno status→Recruiting
  • Kaiser Permanente-Baldwin Park · Baldwin Park, United Statesno status→Recruiting
  • Kaiser Permanente-Bellflower · Bellflower, United Statesno status→Recruiting
  • Alta Bates Summit Medical Center-Herrick Campus · Berkeley, United Statesno status→Recruiting
  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park · Cameron Park, United Statesno status→Recruiting
  • Mercy Cancer Center - Carmichael · Carmichael, United Statesno status→Recruiting
  • Mercy San Juan Medical Center · Carmichael, United Statesno status→Recruiting
  • Mercy Cancer Center - Elk Grove · Elk Grove, United Statesno status→Recruiting
  • Kaiser Permanente-Fontana · Fontana, United Statesno status→Recruiting
  • Palo Alto Medical Foundation-Fremont · Fremont, United Statesno status→Recruiting
  • Kaiser Permanente South Bay · Harbor City, United Statesno status→Recruiting
  • Kaiser Permanente-Irvine · Irvine, United Statesno status→Recruiting
  • Kaiser Permanente Los Angeles Medical Center · Los Angeles, United Statesno status→Recruiting
  • Kaiser Permanente West Los Angeles · Los Angeles, United Statesno status→Recruiting
  • Memorial Medical Center · Modesto, United Statesno status→Recruiting
  • Palo Alto Medical Foundation-Camino Division · Mountain View, United Statesno status→Recruiting
  • Kaiser Permanente-Ontario · Ontario, United Statesno status→Recruiting
  • Palo Alto Medical Foundation Health Care · Palo Alto, United Statesno status→Recruiting
  • Kaiser Permanente - Panorama City · Panorama City, United Statesno status→Recruiting
  • Kaiser Permanente-Riverside · Riverside, United Statesno status→Recruiting
  • Mercy Cancer Center - Rocklin · Rocklin, United Statesno status→Recruiting
  • Sutter Cancer Centers Radiation Oncology Services-Roseville · Roseville, United Statesno status→Recruiting
  • Sutter Roseville Medical Center · Roseville, United Statesno status→Recruiting
  • Mercy Cancer Center - Sacramento · Sacramento, United Statesno status→Recruiting
  • Sutter Medical Center Sacramento · Sacramento, United Statesno status→Recruiting
  • …and 225 more on the registry record
Show 12 added (12 United States)
  • Kootenai Health - Coeur d'Alene · Coeur d'Alene, United States
  • Kootenai Clinic Cancer Services - Post Falls · Post Falls, United States
  • Kootenai Clinic Cancer Services - Sandpoint · Sandpoint, United States
  • SSM Health Good Samaritan · Mount Vernon, United States
  • Minnesota Oncology - Edina · Edina, United States
  • WellSpan Medical Oncology and Hematology · Hanover, United States
  • Billings Clinic Cancer Center · Billings, United States
  • Community Medical Center · Missoula, United States
  • Benefis Sletten Cancer Institute · Great Falls, United States
  • Logan Health Medical Center · Kalispell, United States
  • Community Hospital of Anaconda · Anaconda, United States
  • Bozeman Health Deaconess Hospital · Bozeman, United States
across 15 updates, Sep 30, 2026 – Nov 20, 2026
Eligibility
1 criterion edited
What changed in the criteria
  • EditedParticipants must not be pregnant due to the possibility of harm to the fetus. Individuals who are of reproductive potential must have agreed to use an effective contraceptive method (with details provided as a part of the consent process) during the treatment period and for 5 months after the final dose of atezolizumab. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a sideeffectside effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen
Sep 30, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42949119 ↗
Oct 29, 2026
Site contacts
Changed at 236 sites. See the sites
Show 236 sites
  • Cancer Center at Saint Joseph's · Phoenix, United StatesContact person changed (no phone or email listed)
  • Mayo Clinic Hospital in Arizona · Phoenix, United StatesContact added •••0015Contact added (no phone or email listed)
  • Kaiser Permanente-Anaheim · Anaheim, United StatesContact added c•••@kp.org · •••3996Contact added (no phone or email listed)
  • Sutter Auburn Faith Hospital · Auburn, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
  • Sutter Cancer Centers Radiation Oncology Services-Auburn · Auburn, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
  • Kaiser Permanente-Baldwin Park · Baldwin Park, United StatesContact added c•••@kp.org · •••3996Contact added (no phone or email listed)
  • Kaiser Permanente-Bellflower · Bellflower, United StatesContact added c•••@kp.org · •••3996Contact added (no phone or email listed)
  • Alta Bates Summit Medical Center-Herrick Campus · Berkeley, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park · Cameron Park, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
  • Mercy Cancer Center - Carmichael · Carmichael, United StatesContact person changed (no phone or email listed)
  • Mercy San Juan Medical Center · Carmichael, United StatesContact person changed (no phone or email listed)
  • Mercy Cancer Center - Elk Grove · Elk Grove, United StatesContact person changed (no phone or email listed)
  • Kaiser Permanente-Fontana · Fontana, United StatesContact added c•••@kp.org · •••3996Contact added (no phone or email listed)
  • Palo Alto Medical Foundation-Fremont · Fremont, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
  • Kaiser Permanente South Bay · Harbor City, United StatesContact added c•••@kp.org · •••3996Contact added (no phone or email listed)
  • Kaiser Permanente-Irvine · Irvine, United StatesContact added c•••@kp.org · •••3996Contact added (no phone or email listed)
  • Kaiser Permanente Los Angeles Medical Center · Los Angeles, United StatesContact added c•••@kp.org · •••3996Contact added (no phone or email listed)
  • Kaiser Permanente West Los Angeles · Los Angeles, United StatesContact added c•••@kp.org · •••3996Contact added (no phone or email listed)
  • Memorial Medical Center · Modesto, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
  • Palo Alto Medical Foundation-Camino Division · Mountain View, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
  • Kaiser Permanente-Ontario · Ontario, United StatesContact added c•••@kp.org · •••3996Contact added (no phone or email listed)
  • Palo Alto Medical Foundation Health Care · Palo Alto, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
  • Kaiser Permanente - Panorama City · Panorama City, United StatesContact added c•••@kp.org · •••3996Contact added (no phone or email listed)
  • Kaiser Permanente-Riverside · Riverside, United StatesContact added c•••@kp.org · •••3996Contact added (no phone or email listed)
  • Mercy Cancer Center - Rocklin · Rocklin, United StatesContact person changed (no phone or email listed)
  • Sutter Cancer Centers Radiation Oncology Services-Roseville · Roseville, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
  • Sutter Roseville Medical Center · Roseville, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
  • Mercy Cancer Center - Sacramento · Sacramento, United StatesContact person changed (no phone or email listed)
  • Sutter Medical Center Sacramento · Sacramento, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
  • Kaiser Permanente-San Diego Zion · San Diego, United StatesContact added c•••@kp.org · •••3996Contact added (no phone or email listed)
  • …and 206 more sites
across 11 updates, Sep 30, 2026 – Nov 6, 2026
Show all 17 updates
  1. Nov 20, 2026
    1 site added
    Show site
    • Bozeman Health Deaconess Hospital · Bozeman, United States
  2. Nov 6, 2026
    Duke Cancer Center Cary is now Suspended
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Duke Cancer Center Cary · Cary, United StatesContact removed N•••@dm.duke.eduContact removed (no phone or email listed)
  3. Nov 4, 2026
    1 site added
    Show site
    • Community Hospital of Anaconda · Anaconda, United States
  4. Nov 2, 2026
    Site contacts Changed at 7 sites. See the sites
    Show 7 sites
    • Cancer Center at Saint Joseph's · Phoenix, United StatesContact person changed (no phone or email listed)
    • Mercy Cancer Center - Carmichael · Carmichael, United StatesContact person changed (no phone or email listed)
    • Mercy San Juan Medical Center · Carmichael, United StatesContact person changed (no phone or email listed)
    • Mercy Cancer Center - Elk Grove · Elk Grove, United StatesContact person changed (no phone or email listed)
    • Mercy Cancer Center - Rocklin · Rocklin, United StatesContact person changed (no phone or email listed)
    • Mercy Cancer Center - Sacramento · Sacramento, United StatesContact person changed (no phone or email listed)
    • Woodland Memorial Hospital · Woodland, United StatesContact person changed (no phone or email listed)
  5. Oct 29, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42949119 ↗
    Corewell Health Farmington Hills Hospital is now Recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Corewell Health Farmington Hills Hospital · Farmington Hills, United StatesContact added •••7695Contact added (no phone or email listed)
  6. Oct 27, 2026
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Corewell Health William Beaumont University Hospital · Royal Oak, United StatesSuspended→Recruiting
    • Vanderbilt University/Ingram Cancer Center · Nashville, United StatesSuspended→Recruiting
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Corewell Health William Beaumont University Hospital · Royal Oak, United StatesContact added •••7695Contact added (no phone or email listed)
    • Vanderbilt University/Ingram Cancer Center · Nashville, United StatesContact added •••8480Contact added (no phone or email listed)
  7. Oct 23, 2026
    Corewell Health William Beaumont University Hospital is now Suspended
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Corewell Health William Beaumont University Hospital · Royal Oak, United StatesContact removed •••7695Contact removed (no phone or email listed)
  8. Oct 22, 2026
    2 sites changed recruiting status (2 now suspended)
    Show 2 sites
    • Cancer and Hematology Centers of Western Michigan - Norton Shores · Norton Shores, United StatesRecruiting→Suspended
    • Vanderbilt University/Ingram Cancer Center · Nashville, United StatesRecruiting→Suspended
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Cancer and Hematology Centers of Western Michigan - Norton Shores · Norton Shores, United StatesContact removed c•••@crcwm.org · •••1230Contact removed (no phone or email listed)
    • Vanderbilt University/Ingram Cancer Center · Nashville, United StatesContact removed •••8480Contact removed (no phone or email listed)
  9. Oct 20, 2026
    1 site added. 2 sites changed recruiting status (2 now suspended)
    Show 2 sites
    • Rush-Copley Medical Center · Aurora, United StatesRecruiting→Suspended
    • Rush-Copley Healthcare Center · Yorkville, United StatesRecruiting→Suspended
    Show site
    • Logan Health Medical Center · Kalispell, United States
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Rush-Copley Medical Center · Aurora, United StatesContact removed R•••@rush.edu · •••6212Contact removed (no phone or email listed)
    • Rush-Copley Healthcare Center · Yorkville, United StatesContact removed C•••@rushcopley.com · •••6212Contact removed (no phone or email listed)
  10. Oct 16, 2026
    1 site added
    Show site
    • Benefis Sletten Cancer Institute · Great Falls, United States
  11. Oct 15, 2026
    3 sites changed recruiting status (2 now recruiting, 1 now suspended)
    Show 3 sites
    • Corewell Health Farmington Hills Hospital · Farmington Hills, United StatesRecruiting→Suspended
    • Providence Newberg Medical Center · Newberg, United StatesSuspended→Recruiting
    • Providence Portland Medical Center · Portland, United StatesSuspended→Recruiting
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Corewell Health Farmington Hills Hospital · Farmington Hills, United StatesContact removed •••7695Contact removed (no phone or email listed)
    • Providence Newberg Medical Center · Newberg, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
    • Providence Portland Medical Center · Portland, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
  12. Oct 14, 2026
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Providence Willamette Falls Medical Center · Oregon City, United StatesSuspended→Recruiting
    • Providence Saint Vincent Medical Center · Portland, United StatesSuspended→Recruiting
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Providence Willamette Falls Medical Center · Oregon City, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
    • Providence Saint Vincent Medical Center · Portland, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
  13. Oct 13, 2026
    Greater Regional Medical Center is now Active, not recruiting
  14. Oct 8, 2026
    Minor edits only
    + 1 other change: verification date
  15. Oct 7, 2026
    2 sites changed recruiting status (2 now suspended)
    Show 2 sites
    • Providence Portland Medical Center · Portland, United StatesRecruiting→Suspended
    • Providence Saint Vincent Medical Center · Portland, United StatesRecruiting→Suspended
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Providence Portland Medical Center · Portland, United StatesContact removed C•••@providence.org · •••2614Contact removed (no phone or email listed)
    • Providence Saint Vincent Medical Center · Portland, United StatesContact removed C•••@providence.org · •••2614Contact removed (no phone or email listed)
  16. Oct 5, 2026
    2 sites added
    Show 2 added (2 United States)
    • Billings Clinic Cancer Center · Billings, United States
    • Community Medical Center · Missoula, United States
  17. Sep 30, 2026
    Suspended→Recruiting
    Why stopped Reason for stopping removed
    6 sites added. 255 sites changed recruiting status (234 now recruiting, 14 now suspended, …)
    Show 255 sites
    • Alaska Women's Cancer Care · Anchorage, United Statesno status→Suspended
    • Cancer Center at Saint Joseph's · Phoenix, United Statesno status→Recruiting
    • Mayo Clinic Hospital in Arizona · Phoenix, United Statesno status→Recruiting
    • Kaiser Permanente-Anaheim · Anaheim, United Statesno status→Recruiting
    • Sutter Auburn Faith Hospital · Auburn, United Statesno status→Recruiting
    • Sutter Cancer Centers Radiation Oncology Services-Auburn · Auburn, United Statesno status→Recruiting
    • Kaiser Permanente-Baldwin Park · Baldwin Park, United Statesno status→Recruiting
    • Kaiser Permanente-Bellflower · Bellflower, United Statesno status→Recruiting
    • Alta Bates Summit Medical Center-Herrick Campus · Berkeley, United Statesno status→Recruiting
    • Sutter Cancer Centers Radiation Oncology Services-Cameron Park · Cameron Park, United Statesno status→Recruiting
    • Mercy Cancer Center - Carmichael · Carmichael, United Statesno status→Recruiting
    • Mercy San Juan Medical Center · Carmichael, United Statesno status→Recruiting
    • Mercy Cancer Center - Elk Grove · Elk Grove, United Statesno status→Recruiting
    • Kaiser Permanente-Fontana · Fontana, United Statesno status→Recruiting
    • Palo Alto Medical Foundation-Fremont · Fremont, United Statesno status→Recruiting
    • Kaiser Permanente South Bay · Harbor City, United Statesno status→Recruiting
    • Kaiser Permanente-Irvine · Irvine, United Statesno status→Recruiting
    • Kaiser Permanente Los Angeles Medical Center · Los Angeles, United Statesno status→Recruiting
    • Kaiser Permanente West Los Angeles · Los Angeles, United Statesno status→Recruiting
    • Memorial Medical Center · Modesto, United Statesno status→Recruiting
    • Palo Alto Medical Foundation-Camino Division · Mountain View, United Statesno status→Recruiting
    • Kaiser Permanente-Ontario · Ontario, United Statesno status→Recruiting
    • Palo Alto Medical Foundation Health Care · Palo Alto, United Statesno status→Recruiting
    • Kaiser Permanente - Panorama City · Panorama City, United Statesno status→Recruiting
    • Kaiser Permanente-Riverside · Riverside, United Statesno status→Recruiting
    • Mercy Cancer Center - Rocklin · Rocklin, United Statesno status→Recruiting
    • Sutter Cancer Centers Radiation Oncology Services-Roseville · Roseville, United Statesno status→Recruiting
    • Sutter Roseville Medical Center · Roseville, United Statesno status→Recruiting
    • Mercy Cancer Center - Sacramento · Sacramento, United Statesno status→Recruiting
    • Sutter Medical Center Sacramento · Sacramento, United Statesno status→Recruiting
    • …and 225 more on the registry record
    Show 6 added (6 United States)
    • Kootenai Health - Coeur d'Alene · Coeur d'Alene, United States
    • Kootenai Clinic Cancer Services - Post Falls · Post Falls, United States
    • Kootenai Clinic Cancer Services - Sandpoint · Sandpoint, United States
    • SSM Health Good Samaritan · Mount Vernon, United States
    • Minnesota Oncology - Edina · Edina, United States
    • WellSpan Medical Oncology and Hematology · Hanover, United States
    Eligibility 1 criterion edited
    What changed in the criteria
    • EditedParticipants must not be pregnant due to the possibility of harm to the fetus. Individuals who are of reproductive potential must have agreed to use an effective contraceptive method (with details provided as a part of the consent process) during the treatment period and for 5 months after the final dose of atezolizumab. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a sideeffectside effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen
    Site contacts Changed at 234 sites. See the sites
    Show 234 sites
    • Cancer Center at Saint Joseph's · Phoenix, United StatesContact added R•••@commonspirit.org · •••1881Contact added (no phone or email listed)
    • Mayo Clinic Hospital in Arizona · Phoenix, United StatesContact added •••0015Contact added (no phone or email listed)
    • Kaiser Permanente-Anaheim · Anaheim, United StatesContact added c•••@kp.org · •••3996Contact added (no phone or email listed)
    • Sutter Auburn Faith Hospital · Auburn, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
    • Sutter Cancer Centers Radiation Oncology Services-Auburn · Auburn, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
    • Kaiser Permanente-Baldwin Park · Baldwin Park, United StatesContact added c•••@kp.org · •••3996Contact added (no phone or email listed)
    • Kaiser Permanente-Bellflower · Bellflower, United StatesContact added c•••@kp.org · •••3996Contact added (no phone or email listed)
    • Alta Bates Summit Medical Center-Herrick Campus · Berkeley, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
    • Sutter Cancer Centers Radiation Oncology Services-Cameron Park · Cameron Park, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
    • Mercy Cancer Center - Carmichael · Carmichael, United StatesContact added R•••@commonspirit.org · •••1881Contact added (no phone or email listed)
    • Mercy San Juan Medical Center · Carmichael, United StatesContact added R•••@commonspirit.org · •••1881Contact added (no phone or email listed)
    • Mercy Cancer Center - Elk Grove · Elk Grove, United StatesContact added R•••@commonspirit.org · •••1881Contact added (no phone or email listed)
    • Kaiser Permanente-Fontana · Fontana, United StatesContact added c•••@kp.org · •••3996Contact added (no phone or email listed)
    • Palo Alto Medical Foundation-Fremont · Fremont, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
    • Kaiser Permanente South Bay · Harbor City, United StatesContact added c•••@kp.org · •••3996Contact added (no phone or email listed)
    • Kaiser Permanente-Irvine · Irvine, United StatesContact added c•••@kp.org · •••3996Contact added (no phone or email listed)
    • Kaiser Permanente Los Angeles Medical Center · Los Angeles, United StatesContact added c•••@kp.org · •••3996Contact added (no phone or email listed)
    • Kaiser Permanente West Los Angeles · Los Angeles, United StatesContact added c•••@kp.org · •••3996Contact added (no phone or email listed)
    • Memorial Medical Center · Modesto, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
    • Palo Alto Medical Foundation-Camino Division · Mountain View, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
    • Kaiser Permanente-Ontario · Ontario, United StatesContact added c•••@kp.org · •••3996Contact added (no phone or email listed)
    • Palo Alto Medical Foundation Health Care · Palo Alto, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
    • Kaiser Permanente - Panorama City · Panorama City, United StatesContact added c•••@kp.org · •••3996Contact added (no phone or email listed)
    • Kaiser Permanente-Riverside · Riverside, United StatesContact added c•••@kp.org · •••3996Contact added (no phone or email listed)
    • Mercy Cancer Center - Rocklin · Rocklin, United StatesContact added R•••@commonspirit.org · •••1881Contact added (no phone or email listed)
    • Sutter Cancer Centers Radiation Oncology Services-Roseville · Roseville, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
    • Sutter Roseville Medical Center · Roseville, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
    • Mercy Cancer Center - Sacramento · Sacramento, United StatesContact added R•••@commonspirit.org · •••1881Contact added (no phone or email listed)
    • Sutter Medical Center Sacramento · Sacramento, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
    • Kaiser Permanente-San Diego Zion · San Diego, United StatesContact added c•••@kp.org · •••3996Contact added (no phone or email listed)
    • …and 204 more sites
    + 4 other changes: identifiers, verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05058651
Responsible party
Sponsor
First posted
Sep 28, 2021
Start date
Jun 28, 2022
Primary completion
Oct 1, 2028 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
Nov 20, 2026

Study contacts

David B Zhen
principal investigator · SWOG Cancer Research Network

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atezolizumab

Start the discussion